This findings suggest that gemcitabine plus cisplatin may be effective for BRCA1/2 or PALB2 mutated pancreatic cancer, and the addition of veliparib to gemcitabine/cisplatin chemotherapy may be too toxic [41,42]. This evidence concerns the gene BRCA1 and pancreatic neoplasm.